Peginterferon alfa-2b combined with tenofovir disoproxil fumarate induced high clinical cure rate in inactive chronic hepatitis B virus carriers

Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101723. doi: 10.1016/j.clinre.2021.101723. Epub 2021 Jun 6.

Authors

Xue-Bing Chen¹, Fei-Fei Liu², Fu-Li Shu², Jian-Ying Liu², Jia-Hong Yang²

Affiliations

¹ Department of Infectious Diseases, People's Hospital of Deyang City, Deyang, Sichuan, China. Electronic address: gscxb-11@163.com.
² Department of Infectious Diseases, People's Hospital of Deyang City, Deyang, Sichuan, China.

PMID: 34091082
DOI: 10.1016/j.clinre.2021.101723

No abstract available

Keywords: HBsAg clearance; Inactive hepatitis B virus carriers; Peginterferon alfa-2b; TDF.

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
Drug Therapy, Combination
Hepatitis B, Chronic* / drug therapy
Hepatitis B, Chronic* / virology
Humans
Interferon alpha-2* / therapeutic use
Interferon-alpha* / therapeutic use
Polyethylene Glycols* / therapeutic use
Recombinant Proteins / therapeutic use
Tenofovir* / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
Tenofovir
peginterferon alfa-2b